| Dr David K Knowlton, DDS | |
|
4788 S Redwood Rd, Taylorsville, UT 84123-3147 | |
| (801) 969-4264 | |
| (801) 969-2781 |
| Full Name | Dr David K Knowlton |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 4788 S Redwood Rd, Taylorsville, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003895442 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 145636 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr David K Knowlton, DDS 4788 S Redwood Rd, Taylorsville, UT 84123-3147 Ph: (801) 969-4264 | Dr David K Knowlton, DDS 4788 S Redwood Rd, Taylorsville, UT 84123-3147 Ph: (801) 969-4264 |
News Archive
According to a report from the Israel Cancer Association yesterday (3rd February 2019), there has been a significant fall in the number of Israeli men getting cancers over that last decade.
AlwaysCare Benefits, Inc., one of the country's fastest-growing insurance providers, announced the successful implementation of Plexis Healthcare Systems' Quantum Choice claims processing software to enhance efficient administration of vision benefits on behalf of its insured Members and dependents and its rapidly growing national network of vision care Providers.
Scientists at the Lowy Medical Research Institute have discovered one cause of a progressive, debilitating eye disease called macular telangiectasia type 2 (MacTel).
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).
The U.S. Food and Drug Administration today approved Hiberix, a Haemophilus influenzae Type b (Hib) vaccine, as a booster dose for children 15 months through 4 years old. Hiberix is manufactured by GlaxoSmithKline, with U.S. headquarters in Research Triangle Park, N.C. and Philadelphia.
› Verified 5 days ago
Dr. Matthew Blake Hillstead, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 3105 W 5400 S, Taylorsville, UT 84129 Phone: 801-969-6236 Fax: 801-966-4572 | |
Dr. Benjamin Eugene Werner, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 6151 S Redwood Rd Ste 200, Taylorsville, UT 84123 Phone: 801-441-2144 | |
Dr. James Wylie Thomas, D.M.D. Dentist Medicare: Not Enrolled in Medicare Practice Location: 2195 W 5400 S, Suite 203, Taylorsville, UT 84129 Phone: 801-969-6740 | |
Stephen Eldredge, Dentist Medicare: Not Enrolled in Medicare Practice Location: 5419 S Redwood Rd, Taylorsville, UT 84123 Phone: 801-263-6400 | |
Brian D Duncan, Dentist Medicare: Medicare Enrolled Practice Location: 6183 Prairie View Dr Ste 104, Taylorsville, UT 84118 Phone: 801-969-0881 | |
Brian William Baird, DDS, MS Dentist Medicare: Not Enrolled in Medicare Practice Location: 5547 S 4015 W, Suite #3, Taylorsville, UT 84118 Phone: 801-967-3337 |